11 Most Profitable Large Cap Stocks to Buy According to Analysts

Page 9 of 10

2. Novo Nordisk (NYSE:NVO)

Market Capitalization: $35.49 billion

TTM Net Income: $17.42 billion

Number of Hedge Fund Holders: 60

Analyst Upside Potential: 48.51%

Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo Nordisk (NYSE:NVO) announced that the FDA had approved the use of its new drug Wegovy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis. The drug also moderates advanced liver fibrosis.

The approval follows positive results from the ESSENCE trial, where the drug depicted better results compared to the placebo. At week 72, 36.8% of patients taking Wegovy improved their liver fibrosis without worsening steatohepatitis. Whereas the placebo only improved results in 22.4% of the patients. With the approval, Wegovy is now the first and only GLP-1 drug approved for noncirrhotic metabolic dysfunction-associated steatohepatitis.

Novo Nordisk (NYSE:NVO) is a global healthcare company specializing in diabetes and obesity care.

Page 9 of 10